LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

LOS ANGELES, Feb. 7, 2025 /PRNewswire/ -- Following a comprehensive planning process, 15 independent nonprofit organizations from around the country have formalized ALS United, an innovative ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

The underlying disease process of ALS has long been a mystery, preventing development of effective therapies. Until Siddique’s discovery, scientists weren’t even sure all its forms actually converged ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

After much deliberation, the FDA has granted accelerated approval for Biogen’s tofersen for an ultra-rare form of the neurodegenerative disease amyotrophic lateral sclerosis, associated with a ...

New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

When stress occurs, G3BP1 transitions from a closed, inactive state to an open, active state, enabling stress granules to form and protect the cell. However, the toxic DPRs produced in C9-ALS and ...